Effect of combined conjugated estrogen-medrogestone replacement therapy on lipid profiles, climateric symptoms and the endometrium;Effets sur les lipides, les symptomes climateriques et l'endometre d'une association d'estrogenes conjugues et de medrogestone dans le traitement hormonal substitutif

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 29, Issue 1, 2000, Pages 29-40

  Belaisch, J ^a   Nappi, C ^b   Affinito, P ^b   De Gezelle, H ^c   Botelho, M ^d   Oliveira, H M ^e   Martinez Oliveira, J ^f   Gonzaga, F ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Hospital de St Maria ^*

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Conjugated estrogens; Endometrium; Hormone replacement therapy; Lipids; Medrogestone

Indexed keywords

CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROGESTONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AMENORRHEA; ARTICLE; ASIA; CLIMACTERIUM; CLINICAL TRIAL; DRUG EFFECT; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; EUROPE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; POSTMENOPAUSE; VAGINA BLEEDING;

AGED; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CLIMACTERIC; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LIPIDS; MEDROGESTONE; MIDDLE AGED; PROGESTERONE CONGENERS;

EID: 0034049163     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Grady D, Rubin SM, Petitti DB et coll. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1992; 117: 1016-37.
2. Davis S. Cardiovascular disease prevention in postmenopausal women: a clinician's perspective [Editorial]. Maturitas 1997; 27: 1-3.
3. Belchetz P. Hormonal treatment of postmenopausal women. N Engl J Med 1994; 330: 1062-71.
4. Sarrel PM. Hormone replacement therapy in the menopause. Int J Fertil 1997; 42: 78-84.
5. Woodruff JP, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170: 1213-23.
6. Tikkanen M, Nikkila E, Kuusi T and Spinen S. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 1982; 54: 113-7.
7. Jensen J and Christiansen C. Dose-response effects on serum lipids and lipoproteins following combined estrogen-progesteron therapy in post-menopausal women. Maturitas 1987; 9: 259-66.
8. Pickar J, Thorneycroft I and Whitehead M. Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995. Am J Obstet Gynecol 1998; 178: 1087-99.
9. Speroff L Rowan J, Symons J et al. for the CHART Study Group. The comparative effect on bone density, endometrium and lipids of continuous hormones as replacement therapy: a randomized controlled trial. JAMA 1996; 276: 1397-403.
10. Greendale G, Reboussin B, Hogan P et al. for the Postmenopausal Estrogen/Progestin Interventions Trial investigators. Obstet Gynecol 1998; 92: 982-8.
11. Archer DF, Pickar JH, Bottiglioni F for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994; 83: 686-92.
12. Lobo RA, Pickar JH, Wild RA et coll. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 987-95.
13. Ettinger B, Selby J, Citron J, Vangessel A, Ettinger VM, Hendrickson MR. Cyclic hormone replacement therapy using progestin. Obstet Gynecol 1994; 83: 693-700.
14. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
15. Gevers Leuven J, Van der Mooren M and Buytenhek R. The effect of medrogestone on plasma lipids and lipoproteins in postmenopausal women using conjugated estrogens: an open randomized comparative study. Fertil Steril 1995; 64: 525-31.
16. Sonnendecker E, Polakow E, Spinnler-Benade A and Simchowitz E. Serum lipoprotein effects to conjugated estrogen and a sequential conjugated estrogen-medrogestone regimen in hysterectomized postmenopausal women. Am J Obstet Gynecol 1989; 160: 1128-34.
17. Sitruk-Ware R. Ménopause : quel progestatif choisir? De l'intérêt de la médrogestone (Colprone) dans le traitement hormonal substitutif de la ménopause. Contr Sex Fertil 1987; 15: 975-79.
18. Vingerling JR, Dielmans I, Witteman JCM et coll. Macular degeneration and early menopause; a case-control study. BMJ 1995; 310: 1570-71.
19. The Eye Disease Case-Control Study Group. Risk Factors for Neovascular Age-Related Macular Degeneration. Arch Ophthalmol 1992; 110: 1701-08.
20. Klein BEK, Klein R, Jensen SC et coll. Are Sex Hormones Associated with Age-Related Maculopathy in Women? The Beaver Dam Eye Study. Tr Am Ophth Soc 1994; XCII: 189-97.
21. Nevitt MC, Cummings SR, Lane NE et coll. Association of Estrogen Replacement Therapy with the Risk of Osteoarthritis of the Elderly White Women. Arch Intern Med 1996; 156: 2073-80.
22. Spector TD, Nadra D, Hart DJ et coll. Is hormone replacement therapy protective for hand and knee osteoarthritis in women? The Chingford Study. Ann Rheum Diseases 1997; 56: 432-4.
23. Gordon DJ, Probstfield JL, Garrison RJ et coll. High-density lipoprotein cholesterol and cardiovascular disease, four prospective American studies. Circulation 1989; 79: 8-15.
24. Barrett-Connor E, Sloan S, Greendale G et coll. The postmenopausal estrogen/progestin interventions study: primary out-comes in adherent women. Maturitas 1997; 27: 261-74.
25. Sacks FM, Pfeffer MA, Lemuel AM et coll. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996; 335: 1001-9.
26. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease. The Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-9.
27. Sherwin B and Gelfand M. A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol 1989; 73: 759-66.
28. Huovinen K, Autio S and Kaprio J. Peroral lynestrenol and arterial disease in mentally retarded women. Acta Obstet Gynecol Scand 1988; 67: 211-4.
29. Adams M, Clarkson T, Koritnik D and Nash H. Contraceptive steroids and coronary artery atherosclerosis in cytnomolgus macaques. Fertil Steril 1997; 47: 1010-8.